Genmab Announced That The U.S. FDA Approved EPKINLY For The Treatment Of Adults With Relapsed Or Refractory Follicular Lymphoma After Two Or More Lines Of Systemic Therapy
Portfolio Pulse from Benzinga Newsdesk
Genmab announced that the U.S. FDA approved EPKINLY for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
June 27, 2024 | 6:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genmab's EPKINLY has received FDA approval for treating relapsed or refractory follicular lymphoma in adults after two or more lines of systemic therapy. This approval could lead to increased revenue and market share for Genmab.
FDA approval of a new treatment typically leads to increased sales and market share for the company. Given the specific indication for relapsed or refractory follicular lymphoma, this approval is likely to positively impact Genmab's financial performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100